These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Revisiting interactions between hypoxaemia and beta2 agonists in asthma. Lipworth BJ Thorax; 2001 Jul; 56(7):506-7. PubMed ID: 11413346 [No Abstract] [Full Text] [Related]
43. The FDA and new safety warnings. Moore TJ; Singh S; Furberg CD Arch Intern Med; 2012 Jan; 172(1):78-80. PubMed ID: 22232155 [No Abstract] [Full Text] [Related]
44. FDA reporting program is key to safety information. Young D Am J Health Syst Pharm; 2002 Dec; 59(23):2279, 2284, 2289. PubMed ID: 12489365 [No Abstract] [Full Text] [Related]
45. FDA gets advice on Modernization Act compliance. Marwick C JAMA; 1998 Oct; 280(14):1214-5. PubMed ID: 9786361 [No Abstract] [Full Text] [Related]
46. Regulatory alerts for dietary supplements in Canada and the United States, 2005-13. Abe AM; Hein DJ; Gregory PJ Am J Health Syst Pharm; 2015 Jun; 72(11):966-71. PubMed ID: 25987692 [TBL] [Abstract][Full Text] [Related]
47. FDA needs more sophisticated approach to drug safety. Christie B BMJ; 2005 May; 330(7501):1166. PubMed ID: 15905236 [No Abstract] [Full Text] [Related]
48. Albuterol-induced myocardial ischemia in sickle cell anemia after hemolysis from ceftriaxone administration. Corso M; Ravindranath TM Pediatr Emerg Care; 2005 Feb; 21(2):99-101. PubMed ID: 15699818 [TBL] [Abstract][Full Text] [Related]
49. A warning for the treatment of hyperkalaemia with salbutamol. Semmekrot BA; Monnens LA Eur J Pediatr; 1997 May; 156(5):420. PubMed ID: 9177992 [No Abstract] [Full Text] [Related]
51. The safety of beta agonists in asthma. Morice AH Clin Investig; 1992 Oct; 70(10):949-50. PubMed ID: 1360284 [No Abstract] [Full Text] [Related]
52. Vitamins: the good, the bad and the...deadly? Peters SJ S D Med; 2012 Mar; 65(3):109, 111-2. PubMed ID: 22455164 [No Abstract] [Full Text] [Related]
53. Drug safety takes cooperation. Marwick C JAMA; 1999 Jul; 282(4):315-6. PubMed ID: 10432017 [No Abstract] [Full Text] [Related]
54. Characteristics of Novel Therapeutics and Postmarket Safety Events. Tanimoto T; Mori J; Oshima Y JAMA; 2017 Sep; 318(11):1067. PubMed ID: 28975300 [No Abstract] [Full Text] [Related]
55. Characteristics of Novel Therapeutics and Postmarket Safety Events-Reply. Downing NS; Shah ND; Ross JS JAMA; 2017 Sep; 318(11):1067-1068. PubMed ID: 28975302 [No Abstract] [Full Text] [Related]
56. Opportunities for enhancing the FDA guidance on pharmacovigilance. Psaty BM; Vandenbroucke JP JAMA; 2008 Aug; 300(8):952-4. PubMed ID: 18728269 [No Abstract] [Full Text] [Related]
58. A test before its time? FDA stalls distribution process of proteomic test. Wagner L J Natl Cancer Inst; 2004 Apr; 96(7):500-1. PubMed ID: 15069105 [No Abstract] [Full Text] [Related]
59. [Mortality and beta-agonists, or the risk of statistical inference]. Ribas CD Arch Bronconeumol; 2007 Jul; 43(7):355-7. PubMed ID: 17663886 [No Abstract] [Full Text] [Related]